Cargando…
Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway
BACKGROUND: Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. So, we will exp...
Autores principales: | Ai, Xinghao, Mao, Feng, Shen, Shengping, Shentu, Yang, Wang, Jiejun, Lu, Shun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896077/ https://www.ncbi.nlm.nih.gov/pubmed/29642873 http://dx.doi.org/10.1186/s12885-018-4224-x |
Ejemplares similares
-
Identification of Bexarotene as a PPARγ Antagonist with HDX
por: Marciano, David P., et al.
Publicado: (2015) -
PPARγ/mTOR signalling: striking the right balance in cartilage homeostasis
por: Dell'Accio, Francesco, et al.
Publicado: (2015) -
PPARγ/mTOR Regulates the Synthesis and Release of Prostaglandins in Ovine Trophoblast Cells in Early Pregnancy
por: Hao, Kexing, et al.
Publicado: (2022) -
PPARγ, PTEN, and the Fight against Cancer
por: Teresi, Rosemary E., et al.
Publicado: (2008) -
Fatty acid metabolic reprogramming via mTOR-mediated inductions of PPARγ directs early activation of T cells
por: Angela, Mulki, et al.
Publicado: (2016)